| |
|
|
|
|
|
 |
| |
|
ÀÚÀ̵·Á¤7.5mg ZAIDON TAB. 7.5MG[Acetaminophen , Hydrocodone bitartrate]
|
|
Àü¹®ÀǾàǰ | »èÁ¦
|
|
¸¶¾à
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
645301470[C03800151]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1Á¤(2012.02.01)(ÇöÀç¾à°¡)
\480 ¿ø/1Á¤(2002.10.14)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
³ì»öÀÇ Å¸¿øÇü Á¤Á¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
100Á¤ |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 7.5¹Ð¸®±×·¥ |
100 Á¤ |
º´ |
8806453014708 |
8806453014722 |
|
| 7.5¹Ð¸®±×·¥ |
30 Á¤ |
º´ |
8806453014708 |
8806453014715 |
|
|
| ÁÖ¼ººÐÄÚµå |
313200ATB
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
Áߵ ¹× ½ÉÇÑ ÅëÁõÀÇ ¿ÏÈ
|
| ¾à¹°À½½Ä°£ »óÈ£ÀÛ¿ë |
[Á¶È¸]
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
(Á¤Á¦ 7.5 mg/500 mg)
º¸Åë ¼ºÀÎ ÅëÁõÁ¶ÀýÀ» À§ÇØ ÇÊ¿äÇÑ °æ¿ì 1ȸ 1Á¤À» 4¡6½Ã°£¸¶´Ù °æ±¸Åõ¿©ÇÑ´Ù. 1ÀÏ ÃÖ´ë 6Á¤±îÁö Åõ¿©ÇÑ´Ù.
ÅëÁõÀÇ Á¤µµ¿Í ȯÀÚÀÇ ¹ÝÀÀ¿¡ µû¶ó ¿ë·®À» Á¶ÀýÇÑ´Ù. ±×·¯³ª, È÷µå·ÎÄÚµ·¿¡ ´ëÇÑ ³»¼ºÀÌ ÀÌ ¾àÀ» Áö¼ÓÅõ¿©ÇÔ¿¡ µû¶ó ³ªÅ¸³¯ ¼ö ÀÖ°í, ¿¹±âÄ¡ ¸øÇÑ ÀÌ»ó¹ÝÀÀÀº ¿ë·®ÀÌ Áõ°¡¿Í °ü·ÃÀÖ´Ù´Â Á¡À» ÁÖÀÇÇØ¾ß ÇÑ´Ù.
|
| ÁÖ¿ä¾à¹° »óÈ£ÀÛ¿ë |
[Á¶È¸]
|
| ±Ý±â |
´ÙÀ½ ȯÀÚ¿¡°Ô´Â Åõ¿©ÇÏÁö ¸» °Í.
1) ÀÌ ¾à ¹× ÀÌ ¾àÀÇ ±¸¼º¼ººÐ¿¡ ´ëÇÑ °ú¹Î¹ÝÀÀ ¹× ±× º´·ÂÀÌ Àִ ȯÀÚ
2) ÀÌ ¾à ¶Ç´Â ´Ù¸¥ °¨±â¾à, ÇØ¿ÁøÅëÁ¦¸¦ »ç¿ëÇÑ ÈÄ Ãµ½ÄÀÌ ³ªÅ¸³ º´·ÂÀÌ Àִ ȯÀÚ
3) ÁßÁõ È£Èí¾ïÁ¦ ȯÀÚ(È£Èí¾ïÁ¦°¡ Áõ°µÉ ¼ö ÀÖ´Ù.)
4) µÎ°³³»¾Ð »ó½Â°ú °ü·ÃµÈ µÎºÎÀÇ ±âÁúÀû Àå¾Ö³ª ¼Õ»óÀÌ Àִ ȯÀÚ(È£Èí¾ïÁ¦°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.)
|
| ½ÅÁßÅõ¿© |
´ÙÀ½ ȯÀÚ¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÒ °Í.
1) °í·ÉÀÚ, ¼è¾àÀÚ
2) ÁßÁõ °£¤ý½ÅÀå¾Ö ȯÀÚ(´ë»ç¿Í ¹è¼³ÀÇ Áö¿¬À¸·Î ÀÌ»ó¹ÝÀÀÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.)
3) °©»ó»ùÀúÇÏÁõ(Á¡¾×¼öÁ¾ µî) ȯÀÚ(È£Èí¾ïÁ¦¿Í È¥¼ö°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.)
4) ºÎ½ÅÇÇÁú±â´ÉÀúÇÏÁõ(¿¡µð½¼¾¾º´ µî) ȯÀÚ(È£Èí¾ïÁ¦¿¡ ´ëÇÑ °¨¼ö¼ºÀÌ ³ô¾ÆÁø´Ù.)
5) Àü¸³¼±ºñ´ë¿¡ ÀÇÇÑ ¹è´¢Àå¾Ö, ¿äµµÇùÂø, ¿ä°ü¼ö¼ú ÈÄÀÇ È¯ÀÚ(¹è´¢Àå¾Ö Áõ»óÀÌ ¾Ç鵃 ¼ö ÀÖ´Ù.)
6) È£Èí¾ïÁ¦ ȯÀÚ(È£Èí¾ïÁ¦°¡ Áõ°µÉ ¼ö ÀÖ´Ù.)
7) ¼ö¼ú ÈÄ ¹× ÆóÁúȯ ȯÀÚ(ÀÌ ¾àÀÌ ±âħ¹Ý»ç¸¦ ¾ïÁ¦ÇÑ´Ù.)
8) ±Þ¼º º¹ºÎÁúȯ ȯÀÚ(ÀÓ»ó°æ°ú¸¦ ºÒ¸íÈ®ÇÏ°Ô ÇÏ¿© Á¤È®ÇÑ Áø´ÜÀ» Áö¿¬½Ãų ¼ö ÀÖ´Ù.)
|
| ÀÌ»ó¹ÝÀÀ |
ÀÌ»ó¹ÝÀÀ
1) ÀÌ ¾à°ú °ü·ÃµÈ Áß´ëÇÑ ÀÌ»ó¹ÝÀÀÀº ´ÙÀ½°ú °°´Ù.
¨ç ÀÇÁ¸¼º : °è¼Ó º¹¿ëÀ¸·Î ¸ð¸£ÇÉ°è ¾à¹°°ú À¯»çÇÑ ¾à¹°ÀÇÁ¸¼º°ú ³²¿ëÀÌ »ý±æ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇÏ°í ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
¨è È£Èí¾ïÁ¦ : ¿ë·® ÀÇÁ¸ÀûÀ¸·Î È£Èí¾ïÁ¦ Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î, ÃæºÐÈ÷ °üÂûÇϰí Áõ»óÀÌ ³ªÅ¸³ª¸é ¸¶¾à±æÇ×Á¦(³¯·Ï¼Õ µî) Åõ¿©, È£Èíº¸Á¶ µîÀÇ ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
¨é µÎºÎ¼Õ»ó°ú µÎ°³³»¾Ð »ó½Â : ÀÌ ¾àÀÇ È£Èí¾ïÁ¦ ÀÛ¿ëÀ¸·Î ÀÎÇÑ 2Â÷ÀûÀÎ ³úô¼ö¾× ¾Ð·Â Áõ°¡´Â µÎºÎ¼Õ»ó, ´Ù¸¥ µÎ°³³» º´º¯, ¶Ç´Â ÀÌ¹Ì ÀÖ´ø µÎ°³³»¾Ð »ó½ÂÀ» ´õ¿í ¾ÇȽÃų ¼ö ÀÖ´Ù. ¶ÇÇÑ ¸¶¾à¼º ÁøÅëÁ¦´Â µÎºÎ¼Õ»óÀÌ Àִ ȯÀÚÀÇ ÀÓ»óÀû °æ°ú¸¦ ºÒ¸íÈ®ÇÏ°Ô ÇÒ ¼ö ÀÖ´Ù.
¨ê ¼ï ¹× È£Èí°ï¶õ, Àü½ÅÈ«Á¶, ºÎÁ¾, µÎµå·¯±â µîÀÇ ¾Æ³ªÇʶô½Ã Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇϰí, ÀÌ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÈ÷ óġ¸¦ ÇÑ´Ù.
¨ë µå¹°°Ô ÇǺÎÁ¡¸·¾È ÁõÈıº(½ºÆ¼ºì½º-Á¸½¼ ÁõÈıº), Áßµ¶¼ºÇ¥ÇDZ«»ç¿ëÇØ(¸®¿¤ ÁõÈıº)°¡ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇϰí ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
¨ì õ½Ä Áõ»óÀÌ ³ªÅ¸³ª¸é Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
2) °¡Àå ºó¹øÈ÷ ³ªÅ¸³ª´Â ÀÌ»ó¹ÝÀÀÀº ºñƲ°Å¸², ¾îÁö·¯¿ò, ÁøÁ¤, ¼ûÀÌ Âü, ±¸¿ª, ±¸Åä µîÀÌ´Ù. ÀÌ·¯ÇÑ ÀÌ»ó¹ÝÀÀÀº ´©¿öÀִ ȯÀÚº¸´Ù ¼¼ Ȱµ¿Çϴ ȯÀÚ¿¡°Ô ´õ¿í ÇöÀúÈ÷ ³ªÅ¸³ª¸ç, ȯÀÚ°¡ ´©¿öÀÖÀ¸¸é Áõ»óÀÌ ´Ù¼Ò °æ°¨µÉ ¼ö ÀÖ´Ù.
3) ÁßÃ߽Űæ°è : Á¹À½, È¥¹Ì, È¥¼ö, Á¤½ÅÀû¤ýÀ°Ã¼Àû ÇൿÀå¾Ö, ºÒ¾È, µÎ·Á¿ò, ºÒÄè°¨, ±âºÐº¯È°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
4) ¼Òȱâ°è : Àå±â Åõ¿©·Î º¯ºñ°¡ »ý±æ ¼ö ÀÖ´Ù.
5) ºñ´¢»ý½Ä±â°è : ¸¶¾à¼º ÁøÅëÁ¦ Åõ¿©·Î ¿ä°ü°æ·Ã, ¹æ±¤°ý¾à±Ù °æ·Ã, ¿äÀú·ù µîÀÌ º¸°íµÇ¾ú´Ù.
6) °ú¹Î¹ÝÀÀ : ÇǺΠ¹ßÁø, °¡·Á¿òÀÌ º¸°íµÇ¾ú´Ù.
7) ¾Æ¼¼Æ®¾Æ¹Ì³ëÆæ¿¡ ÀÇÇÑ ½É°¢ÇÑ ÀÌ»ó¹ÝÀÀÀ¸·Î ¾Ë·¹¸£±â ¹ÝÀÀ, ¹ßÁø, Ç÷¼ÒÆÇ°¨¼ÒÁõ, ¹«°ú¸³±¸ÁõÀÌ º¸°íµÇ¾ú´Ù.
|
| »óÈ£ÀÛ¿ë |
»óÈ£ÀÛ¿ë
1) ´Ù¸¥ ¸¶¾à¼º ÁøÅëÁ¦, Àü½Å¸¶ÃëÁ¦, Æä³ëƼ¾ÆÁø°è ¾à¹°, º£Å¸Â÷´ÜÁ¦, ½Å°æ¾ÈÁ¤Á¦, ¼ö¸éÁ¦, »ïȯ°è Ç׿ì¿ïÁ¦ ¶Ç´Â ´Ù¸¥ ÁßÃ߽Űæ¾ïÁ¦Á¦(¾ËÄÚ¿Ã Æ÷ÇÔ)¿Í ÀÌ ¾àÀ» º´¿ëÅõ¿©Çϸé Ãß°¡ÀûÀÎ ÁßÃ߽Űæ¾ïÁ¦ÀÛ¿ëÀÌ À¯¹ßµÇ°í, È£Èí¾ïÁ¦, ÀúÇ÷¾Ð, ±íÀº ÁøÁ¤È¿°ú ¶Ç´Â È¥¼ö°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. µû¶ó¼ ÀÌ·¯ÇÑ ¾à¹°°ú º´¿ëÅõ¿©ÇÏ´Â °æ¿ì¿¡´Â 2°¡Áö ¾à¹° Áß Çϳª, ¶Ç´Â µÑ ´Ù ¿ë·®À» °¨·®ÇØ¾ß Çϸç, ¾ËÄڿðú´Â º´¿ëÅõ¿©ÇÏÁö ¾Ê´Â´Ù.
2) ÀÌ ¾à°ú Ç×Äݸ°Á¦ÀÇ º´¿ë ½Ã ¸¶ºñ¼ºÀåÆó»öÀ¸·Î ÁøÀüµÉ ¼ö ÀÖ´Â ½ÉÇÑ º¯ºñ ¶Ç´Â ¼Òº¯ÃàÀûÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù.
3) ¾Æ¼¼Æ®¾Æ¹Ì³ëÆæ : ¹Ù¸£ºñÅ»°è ¾à¹°, »ïȯ°è Ç׿ì¿ïÁ¦, ¾ËÄÚ¿ÃÀ» Åõ¿©ÇÑ È¯ÀÚ´Â ´Ù·®ÀÇ ¾Æ¼¼Æ®¾Æ¹Ì³ëÆæÀ» ´ë»ç½ÃŰ´Â ´É·ÂÀÌ °¨¼ÒµÇ¾î ¾Æ¼¼Æ®¾Æ¹Ì³ëÆæÀÇ Ç÷Àå ¹Ý°¨±â¸¦ Áõ°¡½Ãų ¼ö ÀÖ´Ù. ¾ËÄÚ¿ÃÀº ¾Æ¼¼Æ®¾Æ¹Ì³ëÆæ °ú·®Åõ¿©ÀÇ °£µ¶¼ºÀ» Áõ°¡½Ãų ¼ö ÀÖ´Ù.
|
| Off-label Usage |
[Á¶È¸]
|
| Related FDA Approved Drug |
±âÁØ ¼ººÐ: HYDROCODONE BITARTRATEACETAMINOPHEN AND HYDROCODONE BITARTRATE (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
ALLAY (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
ANEXSIA (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
ANEXSIA 5/325 (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
ANEXSIA 7.5/325 (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
ANEXSIA 7.5/650 (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
AZDONE (ASPIRIN; HYDROCODONE BITARTRATE)
BANCAP HC (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
CODAMINE (HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
CO-GESIC (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
DURADYNE DHC (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
HOMATROPRINE METHYLBROMIDE AND HYDROCODONE BITARTRATE (HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE)
HYCODAN (HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE)
HYCOMINE (HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
HYCOMINE PEDIATRIC (HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE (HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE)
HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE; IBUPROFEN)
HYDROCODONE COMPOUND (HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE)
HYDROPANE (HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE)
HY-PHEN (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
LORCET-HD (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
LORTAB (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
NORCET (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
NORCO (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
REPREXAIN (HYDROCODONE BITARTRATE; IBUPROFEN)
TUSSIGON (HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE)
TYCOLET (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
VICODIN (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
VICODIN ES (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
VICODIN HP (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
VICOPRIN (ASPIRIN; HYDROCODONE BITARTRATE)
VICOPROFEN (HYDROCODONE BITARTRATE; IBUPROFEN)
ZYDONE (ACETAMINOPHEN; HYDROCODONE BITARTRATE)
±âÁØ ¼ººÐ: ACETAMINOPHENACEPHEN (ACETAMINOPHEN)
ACETAMINOPHEN (ACETAMINOPHEN)
ACETAMINOPHEN AND CODEINE PHOSPHATE (ACETAMINOPHEN; CODEINE PHOSPHATE)
ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE (ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE)
ACETAMINOPHEN, ASPIRIN AND CAFFEINE (ACETAMINOPHEN; ASPIRIN; CAFFEINE)
ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE (ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE)
ACETAMINOPHEN, BUTALBITAL AND CAFFEINE (ACETAMINOPHEN; BUTALBITAL; CAFFEINE)
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE (ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE)
ANOQUAN (ACETAMINOPHEN; BUTALBITAL; CAFFEINE)
BANCAP (ACETAMINOPHEN; BUTALBITAL)
BUCET (ACETAMINOPHEN; BUTALBITAL)
BUTALBITAL ACETAMINOPHEN AND CAFFEINE (ACETAMINOPHEN; BUTALBITAL; CAFFEINE)
BUTALBITAL AND ACETAMINOPHEN (ACETAMINOPHEN; BUTALBITAL)
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE (ACETAMINOPHEN; BUTALBITAL; CAFFEINE)
BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE WITH CODEINE PHOSPHATE (ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE)
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE (ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE)
BUTALBITAL; ACETAMINOPHEN; CAFFEINE; CODEINE (BUTALBITAL; ACETAMINOPHEN; CAFFEINE; CODEINE PHOSPHATE)
BUTAPAP (ACETAMINOPHEN; BUTALBITAL)
CAPITAL AND CODEINE (ACETAMINOPHEN; CODEINE PHOSPHATE)
CODEINE, ASPIRIN, APAP FORMULA NO. 2 (ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE)
CODEINE, ASPIRIN, APAP FORMULA NO. 3 (ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE)
CODEINE, ASPIRIN, APAP FORMULA NO. 4 (ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE)
CODRIX (ACETAMINOPHEN; CODEINE PHOSPHATE)
DARVOCET (ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE)
DARVOCET A500 (ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE)
DARVOCET-N 100 (ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE)
DARVOCET-N 50 (ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE)
DHC PLUS (ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE)
DOLENE AP-65 (ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE)
DRIXORAL PLUS (ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE)
EMPRACET W/ CODEINE PHOSPHATE #3 (ACETAMINOPHEN; CODEINE PHOSPHATE)
EMPRACET W/ CODEINE PHOSPHATE #4 (ACETAMINOPHEN; CODEINE PHOSPHATE)
ESGIC (ACETAMINOPHEN; BUTALBITAL; CAFFEINE)
ESGIC-PLUS (ACETAMINOPHEN; BUTALBITAL; CAFFEINE)
EXCEDRIN (MIGRAINE) (ACETAMINOPHEN; ASPIRIN; CAFFEINE)
FEMCET (ACETAMINOPHEN; BUTALBITAL; CAFFEINE)
FIORICET (ACETAMINOPHEN; BUTALBITAL; CAFFEINE)
FIORICET W/ CODEINE (ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE)
INFANTS' FEVERALL (ACETAMINOPHEN)
INJECTAPAP (ACETAMINOPHEN)
MEDIGESIC PLUS (ACETAMINOPHEN; BUTALBITAL; CAFFEINE)
NEOPAP (ACETAMINOPHEN)
OXYCET (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE)
OXYCODONE 2.5/APAP 500 (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE)
OXYCODONE 5/APAP 500 (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE)
OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE)
PAPA-DEINE #3 (ACETAMINOPHEN; CODEINE PHOSPHATE)
PAPA-DEINE #4 (ACETAMINOPHEN; CODEINE PHOSPHATE)
PERCOCET (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE)
PHENAPHEN W/ CODEINE NO. 2 (ACETAMINOPHEN; CODEINE PHOSPHATE)
PHENAPHEN W/ CODEINE NO. 3 (ACETAMINOPHEN; CODEINE PHOSPHATE)
PHENAPHEN W/ CODEINE NO. 4 (ACETAMINOPHEN; CODEINE PHOSPHATE)
PHENAPHEN-650 W/ CODEINE (ACETAMINOPHEN; CODEINE PHOSPHATE)
PHRENILIN (ACETAMINOPHEN; BUTALBITAL)
PHRENILIN FORTE (ACETAMINOPHEN; BUTALBITAL)
PHRENILIN WITH CAFFEINE AND CODEINE (ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE)
PROPACET 100 (ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE)
PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN (ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE)
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN (ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE)
PROVAL #3 (ACETAMINOPHEN; CODEINE PHOSPHATE)
ROXICET (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE)
ROXICET 5/500 (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE)
ROXILOX (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE)
SEDAPAP (ACETAMINOPHEN; BUTALBITAL)
SYNALGOS-DC-A (ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE)
TALACEN (ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE)
TAVIST ALLERGY/SINUS/HEADACHE (ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE)
TENCON (ACETAMINOPHEN; BUTALBITAL)
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN (ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE)
TRIAD (ACETAMINOPHEN; BUTALBITAL; CAFFEINE)
TRIAPRIN (ACETAMINOPHEN; BUTALBITAL)
TYLENOL (ACETAMINOPHEN)
TYLENOL (CAPLET) (ACETAMINOPHEN)
TYLENOL (GELTAB) (ACETAMINOPHEN)
TYLENOL W/ CODEINE (ACETAMINOPHEN; CODEINE PHOSPHATE)
TYLENOL W/ CODEINE NO. 1 (ACETAMINOPHEN; CODEINE PHOSPHATE)
TYLENOL W/ CODEINE NO. 2 (ACETAMINOPHEN; CODEINE PHOSPHATE)
TYLENOL W/ CODEINE NO. 3 (ACETAMINOPHEN; CODEINE PHOSPHATE)
TYLENOL W/ CODEINE NO. 4 (ACETAMINOPHEN; CODEINE PHOSPHATE)
TYLOX (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE)
TYLOX-325 (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE)
ULTRACET (ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE)
WYGESIC (ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE)
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Dµî±Þ
(Àå±â°£ Åõ¿©Çϰųª °ú·®Åõ¿©½Ã D, ±×·¸Áö ¾ÊÀ¸¸é C )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Acetaminophen¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Acetaminophen¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Acetaminophen is thought to act primarily in the CNS, increasing the pain threshold by inhibiting both isoforms of cyclooxygenase, COX-1 and COX-2, enzymes involved in prostaglandin (PG) synthesis. Unlike NSAIDs, acetaminophen does not inhibit cyclooxygenase in peripheral tissues and, thus, has no peripheral anti-inflammatory affects. While aspirin acts as an irreversible inhibitor of COX and directly blocks the enzyme's active site, studies have found that acetaminophen indirectly blocks COX, and that this blockade is ineffective in the presence of peroxides. This might explain why acetaminophen is effective in the central nervous system and in endothelial cells but not in platelets and immune cells which have high levels of peroxides. Studies also report data suggesting that acetaminophen selectively blocks a variant of the COX enzyme that is different from the known variants COX-1 and COX-2. This enzyme is now referred to as COX-3. Its exact mechanism of action is still poorly understood, but future research may provide further insight into how it works.
Hydrocodone¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Hydrocodone acts as a weak agonist at OP1, OP2, and OP3 opiate receptors within the central nervous system (CNS). Hydrocodone primarily affects OP3 receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as hydrocodone also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.
|
| Pharmacology |
Acetaminophen¿¡ ´ëÇÑ Pharmacology Á¤º¸ Acetaminophen (USAN) or Paracetamol (INN) is a popular analgesic and antipyretic drug that is used for the relief of fever, headaches, and other minor aches and pains. It is a major ingredient in numerous cold and flu medications and many prescription analgesics. It is extremely safe in standard doses, but because of its wide availability, deliberate or accidental overdoses are not uncommon. Acetaminophen, unlike other common analgesics such as aspirin and ibuprofen, has no anti-inflammatory properties or effects on platelet function, and so it is not a member of the class of drugs known as non-steroidal anti-inflammatory drugs or NSAIDs. In normal doses acetaminophen does not irritate the lining of the stomach nor affect blood coagulation, the kidneys, or the fetal ductus arteriosus (as NSAIDs can). Like NSAIDs and unlike opioid analgesics, acetaminophen does not cause euphoria or alter mood in any way. Acetaminophen and NSAIDs have the benefit of being completely free of problems with addiction, dependence, tolerance and withdrawal. Acetaminophen is used on its own or in combination with pseudoephedrine, dextromethorphan, chlorpheniramine, diphenhydramine, doxylamine, codeine, hydrocodone, or oxycodone.
Hydrocodone¿¡ ´ëÇÑ Pharmacology Á¤º¸ Hydrocodone, a semisynthetic opiate agonist and hydrogenated ketone derivative, is similar to other phenanthrene derivatives, such as codeine. Used as an analgesic, hydrocodone is combined with acetaminophen, ibuprofen, or aspirin to treat pain. Used as an antitussive, hydrocodone is combined with phenylephrine, pseudoephedrine, phenylpropanolamine, guaifenesin, pyrilamine, pheniramine, or chlorpheniramine.
|
| Metabolism |
Acetaminophen¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 1A2 (CYP1A2)Cytochrome P450 2E1 (CYP2E1)
Hydrocodone¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 3A4 (CYP3A4)Cytochrome P450 2D6 (CYP2D6)
|
| Protein Binding |
Hydrocodone¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ As most agents in the 5-ring morphinan group of semi-synthetic opioids bind plasma protein to a similar degree (range 19% [hydromorphone] to 45% [oxycodone]), hydrocodone is expected to fall within this range.
|
| Half-life |
Acetaminophen¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 1 to 4 hours
Hydrocodone¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 1.25-3 hours
|
| Absorption |
Acetaminophen¿¡ ´ëÇÑ Absorption Á¤º¸ Rapid and almost complete
Hydrocodone¿¡ ´ëÇÑ Absorption Á¤º¸ Well absorbed from the gastrointestinal tract.
|
| Pharmacokinetics |
AcetaminophenÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ´Ü¹é°áÇÕ : 20-50%
- ´ë»ç :
- »ó¿ë·®¿¡¼ : °£¿¡¼ sulfate¿Í glucuronide Æ÷ÇÕü·Î ´ë»çµÇ¸ç, ¼Ò·®Àº microsomal mixed function oxidases¿¡ ÀÇÇØ ¹ÝÀÀ¼ºÀÌ ¸Å¿ì ³ôÀº Áß°£´ë»çü(acetylimidoquinone)·Î ´ë»çµÈ ÈÄ glutathione Æ÷ÇÕÀ¸·Î ºñȰ¼ºÈµÈ´Ù.
- Áßµ¶·®¿¡¼ (4gÀ» ´Ü ÇÏ·ç º¹¿ëÇÑ Á¤µµ±îÁöµµ Æ÷ÇԵȴÙ) : glutathione Æ÷ÇÕÀÌ Á¡Á¡ ºÒÃæºÐÇÏ°Ô µÇ¾î acetylimidoquinone ³óµµ°¡ Áõ°¡ÇÏ°Ô µÇ¸ç À̰ÍÀÌ °£¼¼Æ÷ ±«»ç¸¦ À¯¹ßÇÏ´Â °ÍÀ¸·Î ¿©°ÜÁö°í ÀÖ´Ù.
- ¹Ý°¨±â
- ½Å»ý¾Æ : 2-5 ½Ã°£
- ¼ºÀÎ
- Á¤»ó ½Å±â´É : 1-3 ½Ã°£
- ¸»±â ½ÅÁúȯ : 1-3 ½Ã°£
- ÃÖ´ëÇ÷Áß³óµµ µµ´Þ½Ã°£
- °æ±¸ : »ó¿ë·® º¹¿ë½Ã 10-60ºÐ, ±Þ¼º Áßµ¶·® º¹¿ë½Ã Áö¿¬µÉ ¼ö ÀÖ´Ù.
|
| Biotransformation |
Acetaminophen¿¡ ´ëÇÑ Biotransformation Á¤º¸ Approximately 90 to 95% of a dose is metabolized in the liver via the cytochrome P450 enzyme pathways (primarily by conjugation with glucuronic acid, sulfuric acid, and cysteine). An intermediate metabolite is hepatotoxic and most likely nephrotoxic and can accumulate after the primary metabolic pathways have been saturated.
Hydrocodone¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic and also in intestinal mucosa.
|
| Toxicity |
Acetaminophen¿¡ ´ëÇÑ Toxicity Á¤º¸ Oral, mouse: LD50 = 338 mg/kg; Oral, rat: LD50 = 1944 mg/kg. Acetaminophen is metabolized primarily in the liver, where most of it is converted to inactive compounds by conjugation with sulfate and glucuronide, and then excreted by the kidneys. Only a small portion is metabolized via the hepatic cytochrome P450 enzyme system. The toxic effects of acetaminophen are due to a minor alkylating metabolite (N-acetyl-p-benzo-quinone imine), not acetaminophen itself nor any of the major metabolites. This toxic metabolite reacts with sulfhydryl groups. At usual doses, it is quickly detoxified by combining irreversibly with the sulfhydryl group of glutathione to produce a non-toxic conjugate that is eventually excreted by the kidneys. The toxic dose of paracetamol is highly variable. In adults, single doses above 10 grams or 140 mg/kg have a reasonable likelihood of causing toxicity. In adults, single doses of more than 25 grams have a high risk of lethality.
Hydrocodone¿¡ ´ëÇÑ Toxicity Á¤º¸ Symptoms of overdose include respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, dizziness, ringing in the ears, confusion, blurred vision, eye problems, cold and clammy skin, and sometimes bradycardia and hypotension. In severe overdose, apnea, circulatory collapse, cardiac arrest and death may occur. LD50=85.7mg/kg (subcutaneous, in mice).
|
| Drug Interactions |
Acetaminophen¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Anisindione Acetaminophen increases the anticoagulant effectWarfarin Acetaminophen increases the anticoagulant effectImatinib Increased hepatic toxicity of both agentsIsoniazid Risk of hepatotoxicityDicumarol Acetaminophen increases the anticoagulant effectDicumarol Increases the anticoagulant effectAcenocoumarol Increases the anticoagulant effect
Hydrocodone¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Cimetidine Cimetidine increases the effect of the narcoticNaltrexone Naltrexone may precipitate a withdrawal syndrome in opiod-dependent individual
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸] Acetaminophen¿¡ ´ëÇÑ P450 table
SUBSTRATES
CYP 2E1
**acetaminophen**
chlorzoxazone
ethanol
INHIBITORS
CYP 2E1
disulfiram
INDUCERS
CYP 2E1
ethanol
isoniazid
|
| Food Interaction |
Acetaminophen¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take without regard to meals.Avoid alcohol (may increase risk of hepatotoxicity).
Hydrocodone¿¡ ´ëÇÑ Food Interaction Á¤º¸ Avoid alcohol.Take with food.To avoid constipation: increase your daily intake of fiber (beans, whole grains, vegetables).
|
| Drug Target |
[Drug Target]
|
| Description |
Acetaminophen¿¡ ´ëÇÑ Description Á¤º¸ Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage. [PubChem]
Hydrocodone¿¡ ´ëÇÑ Description Á¤º¸ Narcotic analgesic related to codeine, but more potent and more addicting by weight. It is used also as cough suppressant. [PubChem]
|
| Dosage Form |
Acetaminophen¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralElixir OralLiquid OralSolution OralSolution / drops OralSuppository RectalSuspension OralSyrup OralTablet OralTablet, effervescent OralTablet, extended release Oral
Hydrocodone¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Syrup OralTablet Oral
|
| Drug Category |
Acetaminophen¿¡ ´ëÇÑ Drug_Category Á¤º¸ Analgesics, Non-NarcoticAntipyretics
Hydrocodone¿¡ ´ëÇÑ Drug_Category Á¤º¸ AnalgesicsAnalgesics, OpioidAntitussive AgentsAntitussivesNarcotics
|
| Smiles String Canonical |
Acetaminophen¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC(=O)NC1=CC=C(O)C=C1
Hydrocodone¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ COC1=C2OC3C(=O)CCC4C5CC(C=C1)=C2C34CCN5C
|
| Smiles String Isomeric |
Acetaminophen¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC(=O)NC1=CC=C(O)C=C1
Hydrocodone¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ COC1=C2O[C@H]3C(=O)CC[C@H]4[C@H]5CC(C=C1)=C2[C@@]34CCN5C
|
| InChI Identifier |
Acetaminophen¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)/f/h9H
Hydrocodone¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-12,17H,4-5,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1
|
| Chemical IUPAC Name |
Acetaminophen¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ N-(4-hydroxyphenyl)acetamide
Hydrocodone¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 4,5-epoxy-3-methoxy-17-methylmorphinan-6-one
|
| Drug-Induced Toxicity Related Proteins |
ACETAMINOPHEN ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Alpha-2A adrenergic receptor Drug:acetaminophen Toxicity:hepatic injury . [¹Ù·Î°¡±â] Replated Protein:Myeloperoxidase Drug:acetaminophen Toxicity:respiratory burst. [¹Ù·Î°¡±â] Replated Protein:Glucose-6-phosphate 1-dehydrogenase Drug:acetaminophen Toxicity:drug-induced hemolysis. [¹Ù·Î°¡±â] Replated Protein:Ornithine decarboxylase Drug:acetaminophen Toxicity:hepatotoxicity. [¹Ù·Î°¡±â] Replated Protein:Lactate dehydrogenase Drug:acetaminophen Toxicity:hepatotoxicity. [¹Ù·Î°¡±â] Replated Protein:Transcription factor AP-1(JUN) Drug:acetaminophen Toxicity:hepatotoxicity. [¹Ù·Î°¡±â] Replated Protein:Haptoglobin Drug:acetaminophen Toxicity:drug-induced hemolysis. [¹Ù·Î°¡±â] Replated Protein:Alanine aminotransferase Drug:acetaminophen Toxicity:hepatotoxicity. [¹Ù·Î°¡±â] Replated Protein:Beta-glucuronidase Drug:acetaminophen Toxicity:hepatotoxin-induced effects. [¹Ù·Î°¡±â] Replated Protein:CYP2E1 Drug:Acetaminophen Toxicity:idiosyncratic hepatotoxicity. [¹Ù·Î°¡±â] Replated Protein:Cytochrome P450 2E1 Drug:acetaminophen Toxicity:hepatotoxicity. [¹Ù·Î°¡±â] Replated Protein:Sulfotransferase family cytosolic Drug:acetaminophen Toxicity:chronic hypoxia. [¹Ù·Î°¡±â] Replated Protein:Cytochrome P450 3A4 Drug:acetaminophen Toxicity:hepatotoxicity. [¹Ù·Î°¡±â] Replated Protein:Caspase recruitment domain-containing protein Drug:acetaminophen Toxicity:hepatotoxicity. [¹Ù·Î°¡±â] Replated Protein:Cytochrome P450 1A2 Drug:acetaminophen Toxicity:hepatotoxicity. [¹Ù·Î°¡±â] ACETAMINOPHEN (APAP) ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Cytochrome P450 Drug:acetaminophen (APAP) Toxicity:renal functional changes, strain-dependent histopathological changes. [¹Ù·Î°¡±â]
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-09-08
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|